Immunovant, Inc. Units

YTD

ALL

Why Robinhood?

You can watch IMVTU and buy or sell other stocks, ETFs, and their options commission-free!

About IMVTU

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor.

CEO

Eric Venker, MD, PharmD

CEOEric Venker, MD, PharmD

Employees

207

Employees207

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

2018

Founded2018

Employees

207

Employees207

IMVTU Key Statistics

Market cap

4.46B

Market cap4.46B

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

183.20

Average volume183.20

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$33.30

52 Week high$33.30

52 Week low

$10.32

52 Week low$10.32